General
Preferred name
TEGLICAR
Synonyms
PH-CBR-2016-001-HVAC-00448-0 ()
P&D ID
PD125847
CAS
250694-07-6
Tags
available
drug candidate
Drug indication
Diabetic complication
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 ¦ÌM and a Ki value of 0.36 ¦ÌM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD)[1][2].
DESCRIPTION Teglicar (ST1326) is a reversible carnitine palmitoyltransferase inhibitor . It is a substrate analogue that mimics palmitoylcarnitine. Teglicar has been investigated for anti-cancer effects in solid and liquid tumours . (GtoPdb)
Cell lines
1
Organisms
0
Compound Sets
5
ChEMBL Drugs
CHEMBL1231506
DrugMAP
DMPCRUT
Guide to Pharmacology
12976
MedChem Express Bioactive Compound Library
HY-16482
ReFrame library
External IDs
17
Properties
(calculated by RDKit )
Molecular Weight
399.35
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
18
Ring Count
0
Aromatic Ring Count
0
cLogP
3.2
TPSA
81.26
Fraction CSP3
0.91
Chiral centers
1.0
Largest ring
0.0
QED
0.27
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Endogenous Metabolite
Pathway
Metabolic Enzyme/Protease
Source data